BRIEF-Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim

Thu May 19, 2016 7:08am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 19 (Reuters) - Horizon Pharma Plc

* Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance

* Also licensed u.s., european and canadian intellectual property rights for interferon gamma-1b for treatment of friedreich's ataxia

* Under terms of separate agreement with undisclosed third party, co licensed u.s., european, canadian ip rights for interferon gamma-1b

* Co will immediately begin investing in related manufacturing, supply chain, regulatory,commercial activities for interferon gamma-1b

* To immediately begin investing in related manufacturing, supply chain, regulatory and commercial activities for interferon gamma-1b

* Paid boehringer ingelheim eur5 million upon signing, will pay eur20 million upon closing for rights for interferon gamma-1b in territories outside u.s, canada, japan

* To Acquire Worldwide Rights To Interferon Gamma-1B from boehringer ingelheim international gmbh Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)